A Novel and Validated Inflammation-Based Prognosis Score (IBPS) Predicts Outcomes in Patients with Diffuse Large B-Cell Lymphoma [Corrigendum]

This article refers to:

A Novel and Validated Inflammation-Based Prognosis Score (IBPS) Predicts Outcomes in Patients with Diffuse Large B-Cell Lymphoma

Liu Y, Sheng L, Hua H, Zhou J, Zhao Y, Wang B. Cancer Manag Res. 2023;15:651–666.

The authors have advised Table 2 on pages 654-656, is incorrect. The correct Table 2 is as follows.

Table 2 Baseline characteristics of patients

Characteristic	Training Set N (%)	Validation Set N (%)	p
Age(years)			0.423
≤60years	92(43.2)	34(38.2)
>60years	121(56.8)	55(61.8)
Gender			0.928
Male	105(49.3)	44(49.4)
Female	108(50.7)	45(50.6)
Ann Arbor stage			0.232
I/II	107(50.2)	38(42.7)
III/IV	106(49.8)	51(57.3)
LDH level(U/L)			0.550
≤245	144(67.6)	57(64.0)
>245	69(32.4)	32(36.0)
EN site involvement			0.121
<2EN sites	162(76.1)	60(67.4)
≥2 EN sites	51(23.9)	29(32.6)
ECOG PS			0.345
0–1	188(88.3)	75(84.3)
≥2	25(11.7)	14(15.7)
B symptoms			0.093
Yes	35(16.4)	22(24.7)
No	178(83.6)	67(75.3)
COO(Hans)			0.960
GCB	94(44.1)	39(43.8)
Non-GCB	119(55.9)	50(56.2)
Response			0.074
CR+PR	183(85.9)	69(77.5)
SD+PD	30(14.1)	20(22.5)
Combined operation			0.313
Yes	80(37.6)	28(31.5)
No	133(62.4)	61(68.5)
Combined radiotherapy			0.567
Yes	57(26.8)	21(23.6)
No	156(73.2)	68(76.4)
NLR			0.663
<4.03	149(70.0)	60(67.4)
≥4.03	64(30.0)	29(32.6)
PLR			0.284
<201.75	139(65.3)	64(71.9)
≥201.75	74(34.7)	25(28.1)
LMR			0.004
<1.91	57(26.8)	39(43.8)
≥1.91	156(73.2)	50(56.2)
AGR			0.006
<1.48	107(50.2)	60(67.4)
≥1.48	106(49.8)	29(32.6)
CAR			0.224
<0.32	156(73.2)	59(66.3)
≥0.32	57(26.8)	30(33.7)
SII			0.531
<878.73	149(70.0)	59(66.3)
≥878.73	64(30.0)	30(33.7)
SIRI			0.261
<1.38	118(55.4)	43(48.3)
≥1.38	95(44.6)	46(51.7)
PNI			0.389
<43.55	75(35.2)	36(40.4)
≥43.55	138(64.8)	53(59.6)
mGPS			0.287
0	151(70.9)	57(64.0)
1	34(12.0)	14(15.7)
2	28(13.1)	18(20.2)
β-2 MG			0.494
<2.50	152(71.4)	60(67.4)
≥2.50	61(28.6)	29(32.6)
MYC			0.179
Negative	75(35.2)	23(25.8)
Positive	64(30.0)	26(29.2)
Unknown	74(34.7)	40(44.9)
BCL2			<0.001
Negative	75(35.2)	28(31.5)
Positive	123(57.7)	45(50.6)
Unknown	15(7.0)	16(17.9)
Ki67			0.964
<90%	137(64.3)	57(64.0)
≥90%	76(35.7)	32(36.0)
IPI			0.006
Low	102(47.9)	38(42.7)
Low-intermediate	50(23.5)	18(20.2)
High-intermediate	47(22.1)	15(16.9)
High	14(6.6)	18(20.2)
NCCN-IPI			0.029
Low	33(15.5)	13(14.6)
Low-intermediate	112(52.6)	38(42.7)
High-intermediate	59(27.7)	26(29.2)
High	9(4.2)	12(13.5)

Abbreviations: AGR, albumin to globulin ratio; COO, cell of origin; CAR, C-reactive protein to albumin ratio; CR, complete remission; EN, extranodal; ECOG PS, Eastern Cooperative Oncology Group Performance Status; GCB, germinal center B-cell-like; IPI, International Prognostic Index; LDH, lactate dehydrogenase; LMR, lympho cyte to monocyte ratio; mGPS, modified Glasgow prognostic score; NCCN, National Comprehensive Cancer Network; NLR, neutrophil to lymphocyte ratio; PR, partial remission; PD, progressive disease; PLR, platelet to lymphocyte ratio; PNI, prognostic nutritional index; SD, stable disease; SIRI, system inflammation response index; SII, systemic immune-inflammation index; β-2 MG, β-2 microglobulin.

Page 663, Figure 6 caption, the text “(D) OS of BCL2 ≥50%; (E) OS of MYC ≥40%” should read “(D) OS of MYC ≥40%; (E) OS of BCL2 ≥50%”.

The authors apologize for these errors and advise they do not affect the results of the paper.